PRESS RELEASE
News
-
-
PRESS RELEASE
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Neuland Laboratories Limited orders raw materials for Phase 1 of macromolecule-enabled transdermal delivery development with LIR Life Sciences Corp. to advance needle-free, skin-applied peptide therapies -
PRESS RELEASE
GLG Life Tech Corporation Reports 2026 First Quarter Financial Results
GLG Life Tech Corporation announces financial results for Q1 2026 with a 26% decrease in revenues. The Company focuses on managing cash flows and improving performance amid competitive price pressure in sweetener market -
PRESS RELEASE
Molten Metals Completes Airborne Geophysical Survey at Texas Project
Molten Metals Corp. completes MobileMT geophysical survey at Texas Project, allowing for refined drilling targets. Focus on key properties following lapsing of Gathering Lake and Triangle Lake projects. Move to semi-annual financial reporting to reduce burden -
PRESS RELEASE
Redwood AI Announces Collaboration with Resilience Biosciences Inc. to Advance AI-Assisted Small-Molecule Drug Development
Redwood AI Corp. collaborates with Resilience Biosciences Inc. for AI-assisted computational chemistry workflows to enhance small-molecule drug development. The partnership aims to streamline early discovery work in the life sciences sector -
-
PRESS RELEASE
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Nanobiotix fully exercises underwriters' over-allotment option, raising gross proceeds of approximately $100 million from global offering. Proceeds allocated for development and general corporate purposes -
PRESS RELEASE
Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Abivax reports Q1 2026 financial results and interim data from UC Study 108, showing strong clinical remission with obefazimod. Cash position at €491.6M. Updates on upcoming trials and financial highlights -
-
